Literature DB >> 11987152

Stat3 activation in prostatic carcinomas.

Rajiv Dhir1, Zuyao Ni, Wei Lou, Fernando DeMiguel, Jennifer Rubin Grandis, Allen C Gao.   

Abstract

BACKGROUND: Activated Stat3 is found in various types of immortal cell lines and cancers. We and others have previously demonstrated that Stat3 is constitutively activated in rat and human prostate cancer cell lines, and that Stat3 activation is involved in IL-6-mediated signaling transduction in prostate cancer cells. The aim of this study is to examine quantitative Stat3 activity in benign and malignant human prostate tissues and analyze the association between Stat3 activity levels and the clinical and pathologic parameters.
METHODS: Stat3 activity levels were analyzed in a total of 104 human primary prostate tissues using electromobility shift assay and immunohistochemical staining for phosphorylated Stat3. The tissue samples used were 42 prostate carcinomas, 42 matched normal prostate tissues from patients with prostatic adenocarcinoma (normal adjacent to tumor), and 20 normal prostate tissues from organ donors.
RESULTS: Significantly higher levels of constitutive Stat3 activity were detected in both prostate carcinomas and the matched normal prostate tissues adjacent to tumors compared to the normal prostates from donors without prostate cancer. There was no significant difference of Stat3 activity in foci of tumor and normal prostate tissue adjacent to tumor. No correlation was seen between Stat3 activity and Gleason grade or serum PSA levels in samples from prostate carcinomas.
CONCLUSIONS: These results indicate that Stat3 is constitutively activated in prostate cancer. The high level of Stat3 activity in both the prostate carcinomas and the normal prostate tissues adjacent to tumors suggests that Stat3 activation may occur before detectable histological alterations of the prostate. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11987152     DOI: 10.1002/pros.10079

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  57 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

Review 2.  Roles and regulation of stat family transcription factors in human breast cancer.

Authors:  Charles V Clevenger
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 3.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

4.  Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.

Authors:  Cheryl D Cropp; Claire L Simpson; Tiina Wahlfors; Nati Ha; Asha George; MaryPat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Tiffany A Green; Teuvo L J Tammela; Joan Bailey-Wilson; Johanna Schleutker
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

5.  MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.

Authors:  Nagalakshmi Nadiminty; Ramakumar Tummala; Wei Lou; Yezi Zhu; Jin Zhang; Xinbin Chen; Ralph W eVere White; Hsing-Jien Kung; Christopher P Evans; Allen C Gao
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

Review 6.  Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.

Authors:  Paul J Toren; Martin E Gleave
Journal:  Asian J Androl       Date:  2013-04-15       Impact factor: 3.285

7.  Activation of Stat3 in renal tumors.

Authors:  Charles Guo; Guanyu Yang; Kyle Khun; Xiantian Kong; David Levy; Peng Lee; Jonathan Melamed
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

8.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.

Authors:  Walid Sasi; Wen G Jiang; Anup Sharma; Kefah Mokbel
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

10.  Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling.

Authors:  Viktor Chesnokov; Chao Sun; Keiichi Itakura
Journal:  Cancer Cell Int       Date:  2009-09-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.